Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19

…, M Cepeda, D Saavedra, Z Mazorra, D Estevez… - Gerontology, 2020 - karger.com
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused
a recent outbreak of coronavirus disease (COVID-19). In Cuba, the first case of COVID-19 …

Treatment of COVID‐19 patients with the anti‐CD6 antibody itolizumab

…, L Cabrera, M Domecq, D Estévez… - Clinical & …, 2020 - Wiley Online Library
Objectives COVID‐19 can lead to a hyperinflammatory state. CD6 is a glycoprotein expressed
on mature T lymphocytes which is a crucial regulator of the T‐cell activation. Itolizumab is …

[HTML][HTML] Safety and efficacy of Racotumomab-Alum vaccine as second-line therapy for advanced non-small cell lung cancer

…, C Viada, R García, M Cepeda, D Estevez… - International Journal of …, 2014 - scirp.org
Despite extensive clinical research in non-small cell lung cancer (NSCLC), overall survival
is still poor. Racotumomab-alum is an anti-idiotypic cancer vaccine that targets NeuGcGM3 …

[HTML][HTML] Specific Immunotherapy in Advanced Cervical-Uterine Cancer Using Humanized Monoclonal Antibody Nimotuzumab and CIMAvax-EGF® Therapeutic …

…, Y Santiesteban, Y Santiesteban, D Estevez… - Journal of Cancer …, 2021 - scirp.org
Cervical uterine cancer represents the fourth most common malignant neoplasm worldwide
in the female sex in terms of incidence, principally from epithelial origen. The high …

Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19 (preprint)

…, M Cepeda, D Saavedra, Z Mazorra, D Estevez… - 2020 - pesquisa.bvsalud.org
IntroductionThe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has
caused a recent outbreak of Coronavirus Disease (COVID-19). In Cuba, the first case of COVID-…

Seguridad del Racotumomab en el tratamiento de pacientes con cáncer de pulmón de células no pequeñas

L Pérez, D Estévez, Y Gastón, A Macías, CE Viada - VacciMonitor, 2013 - scielo.sld.cu
En Cuba, el cáncer de pulmón es el segundo en incidencia y el primero en mortalidad. Por
tanto, se necesita identificar nuevas opciones terapéuticas. Los enfoques inmunológicos son …

Blocking EGFR with nimotuzumab: a novel strategy for COVID-19 treatment

HD Londres, JJ Armada, AH Martínez… - …, 2022 - Future Medicine
Background: Lung injury and STAT1 deficit induce EGFR overexpression in SARS-CoV-2
infection. Patients & methods: A phase I/II trial was done to evaluate the safety and preliminary …

[CITATION][C] Drug accountability in clinical trials

LP Ruiz, LJP Illas, DE Iglesias… - Revista Cubana de …, 2011 - medigraphic.com
Clinical trials are important vehicles for validating new research findings and outcomes to
improve the science of oncology treatment. Ultimately, however, patient safety and quality of …

NeuroEPO plus (NeuralCIM®) in mild-to-moderate Alzheimer's clinical syndrome: the ATHENEA randomized clinical trial

S Sosa, G Bringas, N Urrutia, AI Peñalver… - Alzheimer's Research & …, 2023 - Springer
Background NeuroEPO plus is a recombinant human erythropoietin without erythropoietic
activity and shorter plasma half-life due to its low sialic acid content. NeuroEPO plus prevents …

[BOOK][B] Helicobacter pylori-mediated dysregulation of p120ctn and matrix metalloproteinase-7

SR Ogden - 2009 - search.proquest.com
… Finally, I would like to thank the people who give me a reason to get up and do science
every daymy friends and family. There are too many to name, but I hope you all know you are, …